000 02136cam a2200349 a 4500
003 EG-GiCUC
005 20250223030735.0
008 130109s2012 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.11.22.M.Sc.2012.Am.R
100 0 _aAmr Mohammed Salah Elhennawy
245 1 0 _aRole of ¹⁸F-FDG (fluro-deoxy-glucose) PET/CT in patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative ¹³¹I whole body scan /
_cAmr Mohammed Salah Elhennawy ; Supervised Hosna Mohammed Moustafa , Haitham F. Abdulhamid , Khaled Mohammed Taalab
246 1 5 _aدور المسح الذري المقطعي بالإنبعاث البوزيتروني باستعمال الفلوروديؤكسي جلوكوز المشع المدمج مع الأشعة المقطعيه في مرضى سرطان الغدة الدرقيه النوعى في حالات ارتفاع الثيروجلوبيولين و سلبيه المسح الذري باستخدام اليود المشع
260 _aCairo :
_bAmr Mohammed Salah Elhennawy ,
_c2012
300 _a99 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Nuclear Medicine
520 _aSerum Tg appears to be the most sensitive test in follow up of differentiated cancer thyroid while other imaging methods as ultrasound and CT may be helpful with limited sensitivity. Rising thyroglobulin levels are generally a reliable indicator of recurrent thyroid cancer. This study aimed to detect the ability of 18F-FDG with PET/CT to explain the elevated Tg levels in patients with DCT and negative 131-I WBS
530 _aIssued also as CD
653 4 _a5-flurouracil
653 4 _aDTC
653 4 _aPET/CT
700 0 _aHaitham Fouad Abdulhamid ,
_eSupervisor
700 0 _aHosna Mohammed Moustafa ,
_eSupervisor
700 0 _aKhaled Mohammed Taalab ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c40971
_d40971